Objective To investigate the clinical efficacy of Dengzhan Xixin Injection combined with Edaravone Injection in treatment of hypertensive intracerebral hemorrhage.Methods 100 Patients with hypertensive intracerebral hemorrhage were divided into two groups,with 50 cases every group.The control group patients were treated with intravenous infusion of Edaravone Injection,twice daily,15 mL each time.On the basis of the control group,patients in the treatment group received intravenous drip of Dengzhan Xixin Injection,once daily,40 mL/time.Two groups were treated for 14 d.The clinical efficacy,neurological function,intracranial vascular status,cerebrovascular function,and serum indicators between two groups were compared.Results The total effective rate of the treatment group was higher than that of the control group(96.00%vs 84.00%,P<0.05).NIHSS scores of both groups were decreased(P<0.05),and NIHSS scores in the treatment group was lower than those of the control group(P<0.05).After treatment,the amount of cerebral hematoma,edema,and penumbra area in both groups were decreased(P<0.05).Compared with the control group,the treatment group had lower amounts of cerebral hematoma,edema,and penumbra area(P<0.05).The dynamic resistance and peripheral resistance of both groups were decreased,but the average flow velocity was increased(P<0.05).The dynamic resistance and peripheral resistance of the treatment group were lower than those of the control group,but the average flow velocity was higher than that of the control group after treatment(P<0.05).After treatment,the levels of IL-18,HSP47,CD163,and S100β in both groups were decreased(P<0.05),and these factors in the treatment group were lower than those in the control group(P<0.05).Conclusion The combination of Dengzhan Xixin Injection and Edaravone Injection can improve the therapeutic effect of hypertensive intracerebral hemorrhage,improve neurological function,reduce symptoms of cerebral hematoma,improve cerebrovascular function,and reduce neuroinflammatory injury.
万方数据
